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Duchenne muscular dystrophy (DMD) is the most common hereditary muscular dystrophy
caused by mutation in dystrophin, and there is no curative therapy. Dystrophin is a protein
which forms the dystrophin-associated glycoprotein complex (DGC) at the sarcolemma
linking the muscle cytoskeleton to the extracellular matrix. When dystrophin is absent,
muscle fibers become vulnerable to mechanical stretch. In addition to this, accumulating
evidence indicates DMD muscle having vascular abnormalities and that the muscles
are under an ischemic condition. More recent studies demonstrate decreased vascular
densities and impaired angiogenesis in the muscles of murine model of DMD. Therefore,
generation of new vasculature can be considered a potentially effective strategy for DMD
therapy. The pro-angiogenic approaches also seem to be pro-myogenic and could induce
muscle regeneration capacity through expansion of the satellite cell juxtavascular niche
in the mouse model. Here, we will focus on angiogenesis, reviewing the background,
vascular endothelial growth factor (VEGF)/VEGF receptor-pathway, effect, and concerns of
this strategy in DMD.
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INTRODUCTION
Duchenne muscular dystrophy (DMD) is the most common
hereditary muscular dystrophy affecting approximately 1 in 5000
live male births (Mendell et al., 2012). It is caused by mutations
in dystrophin gene located on Xp21 (Monaco et al., 1986), leading
to progressive muscle weakness in which respiratory and cardiac
failures are the main reasons of their early mortalities. Dystrophin
is a protein which forms the dystrophin-associated glycoprotein
complex (DGC) at the sarcolemma which links the muscle sar-
comeric structure to the extracellular matrix (Davies and Nowak,
2006). When dystrophin is absent due to the gene mutation, mus-
cle fibers become vulnerable to mechanical stretching (Pasternak
et al., 1995). Currently there is no curative therapy for this disease
and glucocorticoid is the only medication available that slows the
decline in muscle strength and function in DMD (Bushby et al.,
2010).
Since the identification of dystrophin in the mid 1980’s
(Monaco et al., 1986), several therapeutic approaches have been
investigated. Gene replacement with virus vector, induction of
protein expression by exon skipping or read through, compen-
sation with dystrophin surrogates, and delivery of muscle stem
cells or pluripotent stem cells have been investigated so far (Leung
and Wagner, 2013; Rodino-Klapac et al., 2013). Recently, it was
announced that phase 3 clinical trial for Drisapersen, an antisense
oligonucleotide for exon skipping, could not meet the endpoint
of statistically significant improvement (http://www.gsk.com/
media.html). Although exon skipping could still be considered as
one of themost promising therapeutic approaches available, there
is a necessity for developing further therapeutic strategies. We
have recently reviewed vasculature-related strategies for DMD,
with a major focus on therapeutic methods to increase blood
flow in existing blood vessels (Ennen et al., 2013). In the cur-
rent review, we examine the evidence for reduced formation of
blood vessels in DMD muscle and the therapeutic approach to
augment angiogenesis by using vascular endothelial growth factor
(VEGF)-based strategies. We provide an update of current evi-
dence for changes in vasculature in DMD, approaches available to
increase vasculature, and further discuss the pros and cons of the
underlying rationale.
EVIDENCE FOR VASCULATURE CHANGES IN DMD
The necrotic fibers in DMD are often seen in groups, a simultane-
ous necrosis of contiguous muscle fibers, and it had been thought
that this phenomenon was due to local reduction of blood supply
by common capillaries in that group of necrotic fibers (Rando,
2001). The dystrophin deficiency in vascular smooth muscle
(Miyatake et al., 1989) and absence of nitric oxide synthase (NOS)
from the sarcolemma have indicated that DMD muscle is sub-
jected to impaired blood flow (Brenman et al., 1995; Rando, 2001;
Ennen et al., 2013).
More recent studies demonstrate that mdx mice muscle has
decreased vascular density. Immunostaining of arterioles has
revealed decreased vascular density in heart and gracilis mus-
cles of mdx mice (Loufrani et al., 2004). Matsakas et al., have
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visually shown that vasculature of the tibialis anterior (TA) in
mdx mice is reduced compared to wild type by microfil-perfused
whole mount imaging (Matsakas et al., 2013).
Another report shows that angiogenesis is impaired in mdx
mice, not only in muscle, but systemically, which was proven by
laser Doppler perfusion imaging in the hind limb ischemicmodel,
VEGF induced neovascularization quantification in the corneal
model, Matrigel subcutaneous angiogenic assay, and quantifica-
tion of tumor growth and vascularization in the tumor implant
model (Palladino et al., 2013).
Rhoads et al., have indicated satellite cells isolated from
aging and mdx mice exhibit decreased expression of hypoxia-
inducible factor 1α (HIF-1α) and VEGF and reduced capacity
to promote angiogenesis in vitro, using a co-culture model of
conditioned media from mdx mice or wild type satellite cells co-
cultured with microvascular fragments (MVFs) (Rhoads et al.,
2009, 2013). They also demonstrated that VEGF mRNA expres-
sion was decreased in proliferating satellite cells in dystrophic
muscle. Furthermore, hypoxic conditions increase VEGF mRNA
expression in satellite cells (Flann et al., 2013).
Taken together, there is a rationale to believe that DMD has
significant defect in vasculature in terms of its quality, quantity,
and angiogenesis, and that the muscles are under an ischemic
condition.
It should be critically discussed whether the vascular change
seen in DMD is a primary effect of the disease or not. Studies
of blood perfusion in mdx mice indicate age or disease progres-
sion may have a major effect in vascular changes. A study with
2-month-old mdx mice showed increased blood flow compared
to the wild type control in the hindlimb ischemia model, whereas
older mice of 6 months showed decreased blood flow (Straino
et al., 2004; Palladino et al., 2013). In wild type mice, it has been
indicated that aged mice have a reduced response to angiogenesis
after ischemia (Palladino et al., 2011, 2012). These data imply that
the vascular changes seen in mdx mice could be the physiological
response to aging and disease progression, rather than being the
primary disease effect.
In one study of gene expression profiling of DMD patients’
muscles, VEGF appears to be lower in DMD than the controls
(Bakay et al., 2002), whereas in another study, a significant dif-
ference was not shown (Haslett et al., 2002). This inconsistency
may be due to the data analysis and differences in experimental
design (Haslett et al., 2002). It also has been reported that blood
VEGF levels are significantly lower in DMD with mean age of
8.1 ± 1.9 years (Abdel-Salam et al., 2009). Others reported that
VEGF levels in serum samples from DMD patients with mean age
of 14.6± 0.8 years was elevated (Saito et al., 2009). Although the
latter study was not compared to age-matched controls, these data
imply that VEGF secretion fluctuates according to age or disease
progression.
Further studies are required to elucidate themechanism of vas-
cular change in DMD, however, the studies designed to improve
vasorelaxation capacity (Ennen et al., 2013) or to increase vas-
culature in order to improve tissue perfusion in DMD animal
models have demonstrated the amelioration of dystrophic pheno-
types (Asai et al., 2007; Verma et al., 2010; Kawahara et al., 2011).
As far as we are aware, the approaches to increase vascular density
have not been applied to humans yet, with animal model studies
showing promising results for DMD therapy (Table 1).
DIFFERENT APPROACHES TO INCREASE VASCULAR
DENSITY IN DMD
VEGF OVEREXPRESSION
VEGF-A (also known as VEGF) is crucial for blood vessel for-
mation during early embryogenesis (Shibuya, 2013). It binds to
VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1) which are the membrane-
spanning tyrosine kinase receptors and both have pro-angiogenic
effects. The major pro-angiogenic effect is generated through Flk-
1, on the other hand, Flt-1 can act negatively in angiogenesis.
Although there is higher affinity to VEGF in Flt-1 compared to
Flk-1 (Sawano et al., 1996), its kinase activity is lower than Flk-1.
Besides full length Flt-1, there is a truncated soluble type (Kendall
and Thomas, 1993) which lacks transmembrane and tyrosine
kinase domains, and is considered to act as decoy receptor of
VEGF.
Overexpression of VEGF via AAV gene transfer in muscles
of mdx mice showed an increased number of capillaries/fibers
(Messina et al., 2007). The treated mdx mice had increased
forelimb strength, reduced necrotic fiber areas, and increased
regenerative fiber areas. Increased capillary density was only seen
in regenerating areas. Although this study also highlights the
role of direct pro-regenerative effect of VEGF to skeletal mus-
cle, they discuss the possible beneficial effects of VEGF-induced
muscle neovascularization on dystrophic muscle as (1) promot-
ing macrophage recruitment and removal of cellular debris; (2)
increasing release and circulation of factors secreted by mononu-
clear cells and activating myogenic cells, and (3) increasing the
recruitment of bone marrow derived mononuclear cells, which in
turn release factors that activate the myogenic process.
VEGF RECEPTOR MODULATION
We recently reported that mdx mice crossed with heterozygous
Flt-1 gene knockout mice (Flt-1+/−) showed increased vascular
density and ameliorated phenotype compared to controlmdx:Flt-
1+/+ mice (Verma et al., 2010; Ennen et al., 2013). Our data
showed that when Flt-1+/− mice were compared with their wild-
type (Flt-1+/+) littermates, Flt-1+/− mice had a significantly
increased number of endothelial cells (ECs) and increased tis-
sue perfusion in TA muscle. When Flt-1+/− mice were crossed
with mdx mice to create double mutant mdx mice with the het-
erozygous allele for Flt-1+/− (mdx:Flt-1+/−) and compared with
their littermates mdx mice with control Flt-1 (mdx:Flt-1+/+)
mice, mdx:Flt-1+/− mice exhibited a higher number of ECs,
increased blood flow and improved muscle function. In these
double mutant mice (mdx:Flt-1+/−), muscle histology suggested
decreased fiber turnover and increased fiber stability. Importantly,
mdx:Flt-1+/− mice display increased number of satellite cells in
the muscle compared to mdx:Flt-1+/+ mice. Satellite cells are
a muscle stem cell population in adult skeletal muscle and are
essential for postnatal muscle growth and regeneration. Asmuscle
ages or is afflicted by disease, muscle regeneration is impaired due
to the decreased number and decreased differentiation capacity
of satellite cells (Mounier et al., 2011). Therefore, it is possi-
ble that an increase in the vascular niche might promote muscle
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Table 1 | Different approaches that could increase vascular density in DMD model animals.
Approach Age of mice at
treatment onset
Outcome References
VEGF overexpression via AAV
gene transfer in mdx mice
4 weeks Increased capillary density in regenerating areas
Reduced necrotic fiber areas
Increased regenerative fiber areas
Increased forelimb strength
Messina et al., 2007
VEGF overexpression via
muscle-derived stem cell
(MDSC) transplantation into
mdx/scid mice
8–10 weeks Increase in angiogenesis
Increase in muscle regeneration
Reduction in fibrosis
Deasy et al., 2009
Genetic modulation of VEGF
receptor (Flt-1) level in mdx
and mdx/utrn−/− mice
2–3 months Increased vascular density
Decreased muscle membrane permeability
Less area of fibrosis and calcification
Decreased centrally located nuclei
Increased tissue perfusion
Improved maximum isometric force and whole-body
tension analysis
Verma et al., 2010
Overexpression of
estrogen-related receptor-γ
(ERRγ)
6–8 weeks Enhanced vasculature and blood flow
Increased number of oxidative myofibers
Improved exercise tolerance
Matsakas et al., 2013
Mesoangioblast
transplantation into the heart
of mdx/utrn−/− mice
4–6 weeks Prevented onset of cardiomyopathy
Increased capillary in the heart
Chun et al., 2013
Treatment with aspirin 4 weeks
(treatment
continued for 7
months)
Increased vascular density
Decreased muscle membrane permeability
Less area of fibrosis
Increased numbers of regenerating fibers
Increased tissue perfusion
Improved resistance to physical exercise
Palladino et al., 2013
regeneration via stimulation of satellite cell proliferation or sur-
vival. These data strongly suggest that Flt-1 haploinsufficiency
ameliorates muscular dystrophy phenotype by developmentally
increased vasculature in mdx mice, further implying the pos-
sibility of VEGF receptor modulation as a therapeutic strategy
(Figure 1).
OTHER APPROACHES THAT CAN INCREASE VASCULAR DENSITY IN
MUSCLE
Estrogen-related receptor-γ (ERRγ) is known to be highly
expressed in skeletal muscles, and it has been demonstrated that
ERRγ can induce angiogenic factors including VEGF to increase
angiogenesis in muscle (Narkar et al., 2011). Matsakas et al.,
reported that ERRγ expression and downstream metabolic and
angiogenic target genes are down-regulated in the skeletal muscles
of mdx mice (Matsakas et al., 2013). In this study, overexpression
of ERRγ selectively in themdxmice skeletal muscle could enhance
vasculature, blood flow, and oxidative myofibers, and improve
exercise tolerance.
Palladino et al., hypothesized that aspirin has beneficial effects
on the angiogenic properties of ECs in dystrophic mice, due to its
ability to enhance NO release from vascular ECs and protective
effect on ECs via the NO cGMP pathway (Palladino et al., 2013).
Treatment with aspirin could enhance production of NO and
cGMP, and long-term low dose aspirin could increase capillary
density, improve resistance to physical exercise, and muscle fiber
permeability.
It is known that exercise training promotes many adaptations
in skeletal muscle, including enhanced angiogenesis (Andersen
and Henriksson, 1977; Gavin et al., 2004). Although exces-
sive exercise may exacerbate the DMD phenotype, these studies
imply that an adequate amount of exercise may be beneficial
to DMD.
CONCERNS REGARDING VEGF ADMINISTRATION AND ITS RECEPTOR
MODULATION
Upon targeting the VEGF/VEGF receptor pathway for ther-
apy, the greatest concern would be whether the newly gener-
ated vasculature was morphologically and functionally sound
in vivo. Although VEGF is a well-known factor for angio-
genesis, it was first described as vascular permeability fac-
tor, and these vascular permeability-producing effects of VEGF
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FIGURE 1 | Schematic figure of relationship between muscle,
capillary, and physiological condition. In mdx mice, capillary density
is decreased, angiogenesis is impaired with decreased flow induced
dilation in arteries. When angiogenesis is enhanced in mdx mice,
increased capillary density and improved angiogenesis capacity leads to
decreased area of necrosis and fibrosis and increased regenerative
capacity in muscle accompanied with increased tissue perfusion and
improved muscle weakness.
may have profound negative consequences in ischemic dis-
ease by augmenting the level of infarcted tissue (Senger et al.,
1983; Weis and Cheresh, 2005). An in vivo imaging study per-
formed in rat skeletal muscle with prolonged expression of
VEGF via AAV vector revealed impaired perfusion of the tis-
sue (Zacchigna et al., 2007). Despite the histological evidence
of neoangiogenesis, resting muscle blood flow measured by
positron emission tomography did not improve, and more-
over, post-exercise muscle blood flow measurements showed
decreased perfusion. This phenomenon was explained by the
formation of leaky vascular lacunae which accounted for the
occurrence of arteriovenous shunts that excluded the downstream
microcirculation.
Although the precise role of Flt-1 in postnatal and adult
tissue angiogenesis still remains ambiguous, a recent study
demonstrated Cre-loxP-mediated conditional knockout mice
with ablated Flt-1 expression in neonatal and adult periods
displaying increased angiogenesis in various tissues including
cornea, lung, heart, brain, kidney, and liver (Ho et al., 2012).
Moreover, the vasculature seen in the conditional Flt-1 knockout
mice matured and perfused properly. These findings are espe-
cially encouraging for developing therapeutic strategies targeting
VEGF/Flt-1 interaction.
COMBINATION THERAPY OF DELIVERING AN ANGIOGENESIS AND
MYOGENESIS FACTOR
Borselli et al. reported that a combination of VEGF to promote
angiogenesis and insulin-like growth factor-1 to directly pro-
mote muscle regeneration could induce functional recovery in
an ischemic injured skeletal muscle in a more prominent manner
than VEGF alone (Borselli et al., 2010). It is also noteworthy that
in their study, sustained delivery of the factors via injectable gel
was effective, whereas bolus delivery did not show any benefit in
terms of angiogenesis, regeneration, and muscle perfusion. These
data imply alternative strategies may be used to obtain more
benefits of angiogenesis therapy in DMD.
THE SIGNIFICANCE OF VEGF/VEGFR PATHWAY IN DMD
DIRECT EFFECT OF VEGF ON SKELETAL MUSCLE
Other than the pro-angiogenic effect, a pro-myogenic effect of
VEGF has been reported in skeletal muscle; however, the effect
of VEGF on muscle cell function is still unclear. The pres-
ence of VEGF receptors has been investigated by several groups.
In vitro experiments using C2C12 cells and primary mouse
myoblasts showed that both Flt-1 and Flk-1 were detected in
western blotting analysis and RT-PCR (Germani et al., 2003;
Arsic et al., 2004), and their expression levels were modu-
lated during the course of differentiation. With normal muscle
tissue, immunohistochemistry data indicated Flt-1 and Flk-1
expression levels in muscle fibers are either very low or null
(Arsic et al., 2004; Wagatsuma et al., 2006; Messina et al.,
2007), but once the muscle was subjected to experimental injury,
both receptors became detectable in satellite cells and regen-
erating muscle fibers (Arsic et al., 2004; Wagatsuma et al.,
2006).
When VEGF was administered to C2C12 cells, cell migra-
tion and survival were enhanced (Germani et al., 2003). Others
have shown an increased number of myotubes expressing myosin
heavy chain (MHC), a myogenic differentiation marker, in
differentiated C2C12 cell cultures supplemented with VEGF
(Arsic et al., 2004). These MHC-positive fibers contained more
multinucleated myofibers while non-VEGF-treated cells con-
sisted mainly of mononuclear myocytes. In addition to these
findings, VEGF-treated cells had significantly longer mono- or
multinucleated MHC-positive cells. Also, when C2C12 cells were
treated with an apoptosis-triggering agent, VEGF could decrease
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the fraction of cells expressing markers of necrosis. It also has
been reported that when human myogenic precursor cells were
incubated with VEGF, there was an increase in cell density
(Christov et al., 2007).
Taken together, it is indicated that VEGFmay have a direct pro-
liferative effect on muscle in addition to promotion of myogenic
fiber growth and an anti-apoptotic effect.
THE PRO-ANGIOGENIC AND PRO-MYOGENIC EFFECTS OF THE
VEGF/VEGFR PATHWAY PLAY AN IMPORTANT ROLE IN THE
REGENERATIVE PROCESS IN MUSCLE
Recent studies highlight the importance of angiogenic and regen-
erative effects of VEGF in muscle regeneration (Beckman et al.,
2013; Bobadilla et al., 2013). Mechanical stimulation (MS) can
increase VEGF secretion (Payne et al., 2007; Cassino et al.,
2012), and MS increases the effectiveness of tissue repair in
muscle-derived stem cell (MDSC) transplantation experiments
in mdx/scid mice (Beckman et al., 2013). Inhibition of VEGF
with soluble Flt-1 (sFlt-1) or short hairpin RNA (shRNA) in
mechanically stimulatedMDSCs (MS-MDSCs) resulted in reduc-
tion of cells’ differentiation and angiogenic capacity within the
transplantation area, both of which are increased in MS-MDSC
transplantation cases (Beckman et al., 2013).
Bobadilla et al., indicated metalloproteinase-10 (MMP-10) has
a role in muscle regeneration in injured or dystrophic muscle
through VEGF/Akt signaling (Bobadilla et al., 2013). MMP-10
protein levels were upregulated in mdx mice, and ablation of
MMP-10 in mdx mice deteriorated the dystrophic phenotype.
Although it was not significant, MMP-10 knockout mice (MMP-
10 KO) crossed with mdx mice had fewer arterioles in the muscle,
and MMP-10 KO had significantly lower number of arterioles
than the wild type control. Various MMPs induce VEGF secre-
tion, and in their study, MMP-10 mRNA silencing in injured wild
type muscle, a decrease in VEGF protein level was observed, while
treatment with recombinant human MMP-10 showed elevated
VEGF (Mott and Werb, 2004; Bobadilla et al., 2013). Collectively,
these data suggest that pro-myogenic and pro-angiogenic effects
of VEGF/VEGFR play an important role in the muscle regenera-
tion process in DMD.
ENDOTHELIAL CELL AND SATELLITE CELL RELATIONSHIP
ECs and factors secreted by them are able to induce satellite
cell proliferation and survival. Christov et al., reported that in
adult normal muscle, satellite cells are located preferentially close
to capillaries, and reciprocally interact with ECs to support the
angio-myogenesis relationship (Christov et al., 2007). Their study
further indicated that there is a correlation between capillary and
satellite cell numbers. In muscle specimens from patients with
amyopathic dermatomyositis (aDM), an inflammatory disease,
capillary density in the muscle is decreased but is spared from
bothmyofiber damage and inflammation. Interestingly, a propor-
tionate decrease in the mean satellite cell number per myofiber
was also observed. Conversely, athletes’ muscles, which have
workload-induced increased capillary density, showed increased
numbers of both capillaries and satellite cells per myofiber.
Indirect coculture using chambers with human umbilical vascular
ECs (HUVECS) or humanmicrovascular ECs (HMECS) cultured
in the upper chamber, and separated with porous filter, human
myogenic precursor cells cultured in the lower chamber, revealed
that an endothelial cell monolayer could increase myogenic cell
growth through soluble factors. EC derived IGF-1, HGF, bFGF,
PDGF-BB, and VEGFwere indicated as effectors formyogenic cell
growth promotion. These data suggest that satellite cell and mus-
cle regeneration are under influence of vasculature and that they
receive supportive cues from ECs to expand and further commit
and differentiate (Mounier et al., 2011).
VASCULAR NETWORK IN DMD CARDIAC MUSCLE AND
POSSIBLE EFFECT OF ANGIOGENESIS
Inmdxmice, it has been reported that there is reduced vasculature
in cardiac tissue compared to the wild-type (Loufrani et al., 2004).
A recent study of postnatal Flt-1 gene ablation, in combination
with left anterior descending artery ligation to create ischemic
cardiomyopathy, showed reduced infarction size and increased
capillary density after ligation (Ho et al., 2012). Chun et al., could
prevent the onset of cardiomyopathy by transplanting mesoan-
gioblast stem cells into the heart of mdx/utrn−/− mice. They
reported increased number of capillaries in the treated hearts,
indicating a possible positive effect on angiogenesis, a well-known
indirect effect of stem cell therapy (Chun et al., 2013). These
data imply that angiogenesis may be beneficial also for DMD
cardiomyopathy.
CONCLUSIONS
Mounting evidence for DMD vascular abnormality indicates
that vascular therapy is a logical approach. Currently, the most
frequently used method to increase vasculature is by modulat-
ing VEGF/VEGFR pathways. DMD muscle may benefit from
angiogenesis in multidimensional aspects. Increasing capillary
density simply resolves ischemia. Direct regenerative and anti-
apoptotic effects of VEGF can be expected. Increased vascular
niches that house satellite cells imply enhanced proliferation
of satellite cells under the influence of supportive cues from
vasculature.
The concern would be whether therapeutically generated vas-
culature is morphologically and functionally beneficial. Although
this issue must be investigated before treating human DMD,
increasing data currently provide strong support that angiogen-
esis is a promising therapeutic strategy for DMD.
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